Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of niclosamide when given together
with enzalutamide in treating patients with castration-resistant prostate cancer that has
come back or has spread to other places in the body. Androgens can cause the growth of
prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by
lowering the amount of androgen the body makes and/or blocking the use of androgen by the
tumor cells. Niclosamide may block signals that enhance prostate cancer cell growth. Giving
enzalutamide and niclosamide may work better in treating patients with castration-resistant
prostate cancer.